Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

Nicole Kucine; Shayla Bergmann; Spencer Krichevsky; Devin Jones; Michael Rytting; Juhi Jain; Carolyn M. Bennett; Linda M.S. Resar; John Mascarenhas; Srdan Verstovsek; Ronald Hoffman

doi:10.1002/pbc.28888

Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

Nicole Kucine, Shayla Bergmann, Spencer Krichevsky, Devin Jones, Michael Rytting, Juhi Jain, Carolyn M. Bennett, Linda M.S. Resar, John Mascarenhas, Srdan Verstovsek, Ronald Hoffman

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

Original language	English
Article number	e28888
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	3
DOIs	https://doi.org/10.1002/pbc.28888
State	Published - Mar 2021

Keywords

essential thrombocytosis
interferon
myeloproliferative neoplasm
polycythemia vera

Access to Document

10.1002/pbc.28888

Cite this

@article{5be2e5d7b18c4c98b862ae3a07475ebb,

title = "Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia",

abstract = "Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.",

keywords = "essential thrombocytosis, interferon, myeloproliferative neoplasm, polycythemia vera",

author = "Nicole Kucine and Shayla Bergmann and Spencer Krichevsky and Devin Jones and Michael Rytting and Juhi Jain and Bennett, {Carolyn M.} and Resar, {Linda M.S.} and John Mascarenhas and Srdan Verstovsek and Ronald Hoffman",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2021",

month = mar,

doi = "10.1002/pbc.28888",

language = "English",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

AU - Kucine, Nicole

AU - Bergmann, Shayla

AU - Krichevsky, Spencer

AU - Jones, Devin

AU - Rytting, Michael

AU - Jain, Juhi

AU - Bennett, Carolyn M.

AU - Resar, Linda M.S.

AU - Mascarenhas, John

AU - Verstovsek, Srdan

AU - Hoffman, Ronald

PY - 2021/3

Y1 - 2021/3

N2 - Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

AB - Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

KW - essential thrombocytosis

KW - interferon

KW - myeloproliferative neoplasm

KW - polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=85098499722&partnerID=8YFLogxK

U2 - 10.1002/pbc.28888

DO - 10.1002/pbc.28888

M3 - Article

C2 - 33381905

AN - SCOPUS:85098499722

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 3

M1 - e28888

ER -

Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this